As of May 29, 2025, ImmunoGen Inc (IMGN) reports a Gross Margin of 99.82%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing ImmunoGen Inc's Gross Margin to Peers
To better understand ImmunoGen Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| ImmunoGen Inc (IMGN) | 99.82% |
| Olema Pharmaceuticals Inc (OLMA) | 7775.20% |
| Shattuck Labs Inc (STTK) | 7775.20% |
| Generation Bio Co (GBIO) | 7775.20% |
| Allovir Inc (ALVR) | 7775.20% |
| Neoimmunetech Inc (950220.KQ) | 7775.20% |
Compared to its competitors, ImmunoGen Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.